6.2 ABO Antibodies, Discrepancies, and Subgroups

6.2 ABO Antibodies, Discrepancies, and Subgroups

Quick Answer: Routine anti-A and anti-B are naturally occurring IgM that react from 4 °C through room temperature, bind complement, and cause intravascular hemolysis. Group O also makes anti-A,B with an IgG component capable of HDFN. Forward type (cells + reagent antibody) must match reverse type (serum + A1 and B reagent cells). Resolve every discrepancy before transfusion. If blood is needed before the problem is solved, issue group O red cells (and AB plasma if plasma is required).

ABO antibodies are the reason ABO remains the most dangerous blood-group system. They are already present in almost every immunocompetent adult, they fix complement, and they do not need a prior transfusion to become lethal. II.B.1 on the June 9, 2026 BB outline tests the antibody as hard as it tests the antigen.

Naturally occurring ABO antibodies

Anti-A and anti-B appear after environmental exposure to similar sugars, usually becoming detectable by 3–6 months of age and reaching adult titers later in childhood. They are predominantly IgM. IgM agglutinates at immediate spin / room temperature, works down to 4 °C, and is an efficient complement binder. Complement activation on an ABO-incompatible red cell produces intravascular hemolysis: hemoglobinemia, hemoglobinuria, DIC, and acute renal injury. That is the classic acute hemolytic transfusion reaction. A 10 mL group A unit into a group O adult is enough to start that cascade. This is not a Kidd-style delayed, extravascular story.

Group O people make anti-A, anti-B, and anti-A,B. The anti-A,B specificity often includes an IgG fraction. IgG crosses the placenta, which is why ABO HDFN is almost always a group O mother with an A or B infant, not an A mother with a B infant. ABO HDFN is usually milder than anti-D HDFN because A and B antigens are not fully developed on fetal cells and because soluble ABH in plasma and tissues can absorb some antibody — but it is real, the DAT can be positive, and the bilirubin can rise. Group O plasma is the “universal plasma” only in the sense that it lacks A and B antigen; it is the worst plasma to give a non-O recipient in volume because it carries both isoagglutinins.

Anti-A1 appears in some A2 (about 1–8%) and more A2B (about 22–35%) people. It is usually IgM, room-temperature, and not clinically significant unless it reacts at 37 °C. Identify it with A2 reverse cells (nonreactive) and Dolichos biflorus (patient cells nonreactive if they are A2). Do not automatically issue group O red cells for every anti-A1; issue them when the antibody is 37 °C reactive or when you cannot finish the workup and the patient is bleeding.

Forward versus reverse

Group A: forward A+, B−; reverse A1 cells −, B cells +. Group B: forward A−, B+; reverse A1 cells +, B cells −. Group O: forward A−, B−; reverse both reagent cells +. Group AB: forward A+, B+; reverse both reagent cells −. A discrepancy is any failure of that pairing. Do not report an ABO type and do not issue type-specific blood until it is resolved. AABB Standards and every hospital SOP agree on that sentence.

Always start a discrepancy with a clerical check (sample label, reagent lot, centrifugation) and a repeat on a washed cell suspension. Many “discrepancies” die there. What remains falls into four buckets: extra reverse, missing reverse, extra forward, missing forward.

Extra reactions in the reverse type

Unexpected agglutination of A1 or B reagent cells usually means an extra antibody, not an extra antigen.

• Cold autoantibody (often anti-I): auto control and screening cells also positive at RT/4 °C. Warm the test, use a prewarm technique, or adsorb the cold auto. The ABO type is still there once the cold is out of the way.
• Rouleaux (paraprotein, dextran, high protein): stacked-coin appearance under the microscope. Saline replacement disperses rouleaux; true agglutination remains. Do not call rouleaux an alloantibody and do not skip the microscope.
• Passive ABO antibody: recent transfusion of group O platelets or plasma, IVIG, or passenger-lymphocyte antibody after transplant. Check the transfusion and transplant history before inventing a new blood type.
• Anti-A1 in an A2 or A2B patient: A1 cells positive, A2 cells negative, Dolichos negative on the patient cells.
• Alloantibody to an antigen on the reverse cells, often a cold alloantibody such as anti-M, anti-P1, or anti-Le(a). Panel the antibody. Reverse cells are not specially typed to avoid every low-frequency antigen.

Missing reactions in the reverse type

Expected anti-A or anti-B is weak or absent.

• Newborns and infants do not have reliable isoagglutinins. Reverse typing is not used to assign an infant ABO type; forward type (and the mother’s type) drive component choice. A 3-day-old with a clean forward A and a blank reverse is not a discrepancy — it is a neonate.
• Elderly patients, immunosuppression, hypogammaglobulinemia, CLL, and congenital immunodeficiency lower isoagglutinin titers.
• Dilution after massive transfusion or plasma exchange can empty the reverse.
• Incubate a missing reverse at room temperature or 4 °C, add more serum, and check the immunoglobulin and drug history. Do not “fix” a missing reverse by simply recording the forward type on an adult.

Extra reactions in the forward type

Unexpected antigen typing is the bucket that includes the classic acquired-B item.

• Acquired B: a group A patient, usually with a gram-negative GI infection, bowel obstruction, or colon cancer, acquires a bacterial deacetylase that converts A-antigen GalNAc toward a B-like galactose. Forward type looks AB; reverse looks A (anti-B is still present). Confirm by acidifying anti-B to about pH 6.0 — acquired B reactivity disappears, true B does not. Autocontrol is typically negative. Some monoclonal anti-B clones never detect acquired B. Treat the infection; the phenomenon fades. Transfuse as group A, not AB.
• B(A) phenotype: an overactive B transferase adds a little GalNAc. Some monoclonal anti-A reagents pick it up. Reverse is group B. Change the anti-A clone or use a polyclonal reagent.
• Transplantation: hematopoietic progenitor cell transplant can change the forward type over weeks; passenger lymphocytes can change the reverse. Solid-organ transplant can transfer lymphocytes that make donor-type ABO antibody.
• Wharton’s jelly on cord samples causes nonspecific aggregation. Wash the cord cells thoroughly before you believe an AB forward type on a newborn.
• Polyagglutination, antibody-coated cells, and unwashed cold-auto cells can also extra-react.

Missing reactions in the forward type

Expected A or B is weak or absent.

• Weak subgroups (A3 mixed-field, Ax reacting mainly with anti-A,B, Am/Ael needing adsorb-elute). Use anti-A,B, extended incubation, and adsorption-elution before you relabel a patient as group O.
• Chimerism (twin, dispermy) or recent stem-cell transplant — mixed-field that is a real dual population, not A3. The history and a molecular ABO type settle it.
• Massive transfusion of group O red cells to a non-O patient creates a temporary O-like forward type.
• Some leukemias and MDS weaken A or B antigen. The reverse type and the historical type save you.

Urgent transfusion and the only safe delay

If the discrepancy cannot be finished and red cells are needed now, issue group O red cells (D-matched if time allows) and group AB plasma. Document the emergency release. Do not issue a “best guess” type-specific unit. The whole point of reverse typing is that a wrong guess is intravascular hemolysis. Once the type is resolved, switch to type-specific inventory; do not stay on group O forever without a reason.

Exam traps

• Calling anti-A1 automatically clinically significant. Honor it only if it is 37 °C / AHG reactive.
• Treating acquired B as a true AB person and issuing AB red cells. Acidify the anti-B; transfuse as group A.
• Reverse-typing a neonate and “correcting” the type to match missing antibodies.
• Using plasma exchange language when the problem is rouleaux — the move is saline replacement.
• Releasing type-specific blood “overnight” and promising to resolve the discrepancy on the next shift.
• Mixing extra reverse (antibody problem) with extra forward (antigen or artifact problem) in the same sentence.